AnitaA.KohliMD
Ophthalmology • New Haven, CTNeuro-Ophthalmology, Pediatric & Strabismus
Yale Departments of Ophthalmology & Visual Science and Neurology
Dr. Kohli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
40 Temple St
Ste 1B
New Haven, CT 06510Phone+1 203-785-3360
Education & Training
University of Pennsylvania Health SystemFellowship, Neuro-Ophthalmology, 2016 - 2017- University of Pennsylvania Health System/Scheie Eye InstituteResidency, Ophthalmology, 2013 - 2016
University of MarylandInternship, Internal Medicine, 2012 - 2013
University of Maryland School of MedicineClass of 2012
Certifications & Licensure
CT State Medical License 2017 - 2025
PA State Medical License 2013 - 2018- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Publications & Presentations
PubMed
- 5 citationsUtility of Spectral-Domain Optical Coherence Tomography in Differentiating Papilledema From Pseudopapilledema: A Prospective Longitudinal Study.Imran Jivraj, Cesar A Cruz, Maxwell Pistilli, Anita A. Kohli, Grant T. Liu
Journal of Neuro-Ophthalmology. 2021-12-01 - 42 citationsA phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes.Stephen A. Harrison, Nadege Gunn, Guy W. Neff, Anita Kohli, Liping Liu
Nature Communications. 2021-09-17 - 11 citationsSafety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.Stephen A. Harrison, Seth J. Baum, Nadege Gunn, Ziad Younes, Anita Kohli
The American Journal of Gastroenterology. 2021-08-12
Press Mentions
PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD - the Liver Meeting® 2024November 18th, 2024- PharmaIN to Present Promising Interim Data from Its Ongoing Phase 1 Trial of PHIN-214, an Optimized Vasopressor for Decompensated Cirrhosis, at the Liver Meeting® 2024October 16th, 2024
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
